Dr. Eric Nuermberger, professor in the Division of Infectious Diseases, is a co-principal investigator of the Preclinical Design and Clinical Translation of TB Regimens (PReDicTR) Consortium, recently awarded $30.8M over five years from the NIH's National Institute of Allergy and Infectious Diseases. PReDicTR brings together a multidisciplinary group of scientists, drug developers, and others to assess the evolving preclinical research landscape in the fight against tuberculosis. The consortium hopes to identify novel regimens that have the most significant potential for success in treating adults and children with TB.
Nuermberger Co-PI on Team Awarded $30.8M to Fight TB
